Qualitative and quantitative assessment of process related impurities in Brigatinib raw material and formulations using HPLC

Abstract

The presence of process related impurities in any drug or the drug product was associated with its safety, stability and efficacy. The overall literature survey proved that there is no method published on the assessment of process related impurities in brigatinib. In this study, a simple, reliable and stable HPLC qualitative method was reported for quantification of process related impurities with easy and quick extraction procedure. The impurities along with standard brigatinib was resolved on Lichrospher®C18 (250 mm × 4.6 mm; 5 μm particle size) column in room temperature using methanol, acetonitrile, pH 4.5 phosphate buffer in 55:25:20 (v/v) at 1.0 mL/min as mobile phase and UV detection at 261 nm. The method produces well resolved peaks at retention time of 4.60 min, 12.28 min, 3.37 min, 7.34 min and 8.39 min respectively for brigatinib, impurity A, B, C and D. The method produces a very sensitive detection limit of 0.0065 μg/mL, 0.0068 μg/mL, 0.0053 μg/ mL and 0.0058 μg/mL for impurity A, B, C and D respectively with calibration curve linear in the concentration range of 22.5-135 μg/mL for brigatinib and 0.0225-0.135 μg/mL for impurities. The method produces all the validation parameters under the acceptable level and doesn’t produces any considerable changes in peak area response while minor changes in the developed method conditions. The method can effectively resolve the unknown stress degradation products along with known impurities with less % degradation. The method can efficiently resolve and quantify the impurities in formulation and hence can suitable for the routine quality analysis of brigatinib in raw material and formulation.